

Chapter 232

Oral Antifungal Agents

Reza Jacob & Nellie Konnikov

REFERENCES

1. Elewski BE, Hay RJ: Novel treatment strategies for superficial mycoses: Introduction. *J Am Acad Dermatol* **40**:S1–S2, 1999
2. Favre B, Ryder NS: Characterization of squalene epoxidase activity from the dermatophyte *Trichophyton rubrum* and its inhibition by terbinafine and other antimycotic agents. *Antimicrob Agents Chemother* **40**:443–447, 1996
3. Katz HI: Drug interactions of the newer oral antifungal agents. *Br J Dermatol* **141**(Suppl. 56):26–32, 1999
4. Ryder NS: Terbinafine: Mode of action and properties of the squalene epoxidase inhibition. *Br J Dermatol* **126**(Suppl. 39):2–7, 1992
5. Jensen JC: Clinical pharmacokinetics of terbinafine (Lamisil). *Clin Exp Dermatol* **14**:110–113, 1989
6. Balfour JA, Faulds D: Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. *Drugs* **43**:259–284, 1992
7. Lamisil Oral Granules [prescribing information]. Stein, Switzerland, Novartis Pharma Stein AG, 2007
8. Elewski BE et al: Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: Rof two randomized, investigator-blinded, multicenter, international, controlled trials. *J Am Acad Dermatol* **59**:41–54, 2008
9. Gupta AK, Skinner AR: Onychomycosis in children: A brief overview with treatment strategies. *Pediatr Dermatol* **21**:74–79, 2004
10. Lamisil. *PDR Guide to Drug Interactions, Side Effects, and Indications*. Montvale, NJ, Thomson PDR, 2006
11. Sigurgeirsson B et al: L.I.ON. Study: Efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. Itraconazole in onychomycosis. *Br J Dermatol* **141**(Suppl. 56):5–14, 2002
12. Sigurgeirsson B et al: Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: A 5-year blinded prospective follow-up study. *Arch Dermatol* **138**:353–357, 2002
13. De Cuyper C, Hindryckx PH: Long-term outcomes in the treatment of toenail onychomycosis. *Br J Dermatol* **141**(Suppl. 56):15–20, 1999
14. De Backer M, et al: Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: A double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. *J Am Acad Dermatol* **38**:S57–S63, 1998
15. Sigurgeirsson B et al: Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: A randomized, double-blind comparison. *J Dermatolog Treat* **17**:38–44, 2006
16. Gupta AK et al: The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis. *J Eur Acad Dermatol Venereol* **23**:256–262, 2009
17. Jennings MB et al: Treatment of toenail onychomycosis with oral terbinafine plus aggressive debridement: IRON-CLAD, a large, randomized, open-label, multicenter trial. *J Am Podiatr Med Assoc* **96**:465–473, 2006
18. Potter LP: The impact of aggressive debridement used as an adjunct therapy with terbinafine on perceptions of patients undergoing treatment for toenail onychomycosis. *J Dermatolog Treat* **18**:46–52, 2007
19. Avner S, Nir N, Henri T: Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis. *J Dermatolog Treat* **16**:327–330, 2005
20. Baran R et al: A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. *Br J Dermatol* **157**:149–157, 2007
21. Villars V, Jones TC: Clinical efficacy and tolerability of terbinafine (Lamisil)—A new topical and systemic fungicidal drug for treatment of dermatomycoses. *Clin Exp Dermatol* **14**:124–127, 1989
22. Lamisil [prescribing information]. Stein, Switzerland, Novartis Pharma Stein AG, 2001

23. Scaparro E et al: Evaluation of the efficacy and tolerability of oral terbinafine (Daskil) in patients with seborrhoeic dermatitis. A multicentre, randomized, investigator-blinded, placebo-controlled trial. *Br J Dermatol* **144**:854-857, 2001
24. Vena GA et al: Oral terbinafine in the treatment of multi-site seborrhoeic dermatitis: A multicenter, double-blind placebo-controlled study. *Int J Immunopathol Pharmacol* **18**:745-753, 2005
25. Budimulja U, Paul C: One-week terbinafine 1% solution in pityriasis versicolor: Twice-daily application is more effective than once-daily. *J Dermatolog Treat* **13**:39-40, 2002
26. Gupta AK, Konnikov N, Lynde CW: Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. *J Am Acad Dermatol* **44**:479-484, 2001
27. Tavakkol A, Fellman S, Kianifard F: Safety and efficacy of oral terbinafine in the treatment of onychomycosis: Analysis of the elderly subgroup in Improving Results in ONychomycosis-Concomitant Lamisil and Debridement (IRON-CLAD), an open-label, randomized trial. *Am J Geriatr Pharmacother* **4**:1-13, 2006
28. Kovacs MJ et al: Neutropenia and pancytopenia associated with oral terbinafine. *J Am Acad Dermatol* **31**:806, 1994
29. Roberts DT: Oral terbinafine (Lamisil) in the treatment of fungal infections of the skin and nails. *Dermatology* **194**(Suppl. 1):37-39, 1997
30. Wilson NJ, Evans S: Severe pustular psoriasis provoked by oral terbinafine. *Br J Dermatol* **139**:168, 1998
31. Bong JL, Lucke TW, Evans CD: Persistent impairment of taste resulting from terbinafine. *Br J Dermatol* **139**:747-748, 1998
32. Brooke R, Coulson IH, al-Dawoud A: Terbinafine-induced subacute cutaneous lupus erythematosus. *Br J Dermatol* **139**:1132-1133, 1998
33. Dupin N et al: Acute generalized exanthematous pustulosis induced by terbinafine. *Arch Dermatol* **132**:1253-1254, 1996
34. Gupta AK: Hepatitis associated with terbinafine therapy: Three case reports and a review of the literature. *Clin Exp Dermatol* **23**:64-67, 1998
35. Lowe G, Green C, Jennings P: Hepatitis associated with terbinafine treatment. *BMJ* **306**:248, 1993
36. Ornstein DL, Ely P: Reversible agranulocytosis associated with oral terbinafine for onychomycosis. *J Am Acad Dermatol* **39**:1023-1024, 1998
37. Carstens J, et al: Toxic epidermal necrolysis and erythema multiforme following therapy with terbinafine. *Acta Derm Venereol* **74**:391-392, 1994
38. Brodell RT, Elewski BE: Clinical pearl: Systemic antifungal drugs and drug interactions. *J Am Acad Dermatol* **33**:259-260, 1995
39. Smith EB: The treatment of dermatophytosis: Safety considerations. *J Am Acad Dermatol* **43**:S113-S119, 2000
40. Abdel-Rahman SM, et al: Investigation of terbinafine as a CYP2D6 inhibitor in vivo. *Clin Pharmacol Ther* **65**:465-472, 1999
41. Hall M et al: Safety of oral terbinafine: Results of a postmarketing surveillance study in 25,884 patients. *Arch Dermatol* **133**:1213-1219, 1997
42. van der Kuy PH, Hooymans PM: Nortriptyline intoxication induced by terbinafine. *BMJ* **316**:441, 1998
43. Schmutz JL, Barbaud A, Trechot P: [Overdose of nortriptyline during treatment with terbinafine (1st reported case)]. *Ann Dermatol Venereol* **126**:647, 1999
44. Heykants J et al: The clinical pharmacokinetics of itraconazole: An overview. *Mycoses* **32**(Suppl. 1):67-87, 1989
45. Friedlander SF: The optimal therapy for tinea capitis. *Pediatr Dermatol* **17**:325-326, 2000
46. Haria M, Bryson HM, Goa KL: Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. *Drugs* **51**:585-620, 1996
47. Van Cutsem J: The in-vitro antifungal spectrum of itraconazole. *Mycoses* **32**(Suppl. 1):7-13, 1989
48. Vanden Bossche H et al: Biochemical basis for the activity and selectivity of oral antifungal drugs. *Br J Clin Pract Suppl* **71**:41-46, 1990
49. Barone JA et al: Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. *Antimicrob Agents Chemother* **37**:778-784, 1993
50. Zimmermann T et al: Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. *Eur J Clin Pharmacol* **46**:147-150, 1994
51. Negroni R, Arechavala AI: Itraconazole: Pharmacokinetics and indications. *Arch Med Res* **24**:387-393, 1993
52. Van de Velde VJ et al: Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole. *Pharmacotherapy* **16**:424-428, 1996

53. Steinbach WJ: Antifungal agents in children. *Pediatr Clin North Am* **52**:895-915, viii, 2005
54. SporanoX. *PDR Guide to Drug Interactions, Side Effects, and Indications*. Montvale, NJ, Thomson PDR, 2006
55. Gupta AK, Cooper EA, Ginter G: Efficacy and safety of itraconazole use in children. *Dermatol Clin* **21**:521-535, 2003
56. Elewski BE: Treatment of tinea capitis: Beyond griseofulvin. *J Am Acad Dermatol* **40**:S27-30, 1999
57. Elewski BE: New developments in cutaneous fungal infections. *Curr Probl Dermatol* **12**:81-85, 2000
58. Gupta AK et al: Therapeutic options for the treatment of tinea capitis caused by Trichophyton species: Griseofulvin versus the new oral antifungal agents, terbinafine, itraconazole, and fluconazole. *Pediatr Dermatol* **18**:433-438, 2001
59. Gupta AK et al: Tinea capitis: An overview with emphasis on management. *Pediatr Dermatol* **16**:171-189, 1999
60. Havu V et al: A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. *Br J Dermatol* **136**:230-234, 1997
61. Gupta AK et al: Itraconazole for the treatment of tinea pedis: A dosage of 400 mg/day given for 1 week is similar in efficacy to 100 or 200 mg/day given for 2 to 4 weeks. *J Am Acad Dermatol* **36**:789-792, 1997
62. Gupta AK et al: Superficial fungal infections: an update on pityriasis versicolor, seborrheic dermatitis, tinea capitis, and onychomycosis. *Clin Dermatol* **21**:417-425, 2003
63. Gupta AK et al: Hepatic safety of itraconazole. *J Cutan Med Surg* **6**:210-213, 2002
64. Tucker RM et al: Adverse events associated with itraconazole in 189 patients on chronic therapy. *J Antimicrob Chemother* **26**:561-566, 1990
65. Rosen T: Debilitating edema associated with itraconazole therapy. *Arch Dermatol* **130**:260-261, 1994
66. SporanoX [prescribing information]. Titusville, NJ, Janssen Pharmaceutica, 2004
67. Viagra [prescribing information]. New York, Pfizer, 2000
68. Friedlander SF: Tinea capitis—Past, present and future. *Curr Probl Dermatol* **30**:278-281, 2000
69. Montero-Gei F: Fluconazole: Pharmacokinetics and indications. *Arch Med Res* **24**:377-385, 1993
70. Thorpe JE, Baker N, Bromet-Petit M: Effect of oral antacid administration on the pharmacokinetics of oral fluconazole. *Antimicrob Agents Chemother* **34**:2032-2033, 1990
71. Dudley MN: Clinical pharmacology of fluconazole. *Pharmacotherapy* **10**:141S-145S, 1990
72. Tucker RM et al: Treatment of coccidioidal meningitis with fluconazole. *Rev Infect Dis* **12**(Suppl. 3):S380-9, 1990
73. Brammer KW, Farrow PR, Faulkner JK: Pharmacokinetics and tissue penetration of fluconazole in humans. *Rev Infect Dis* **12**(Suppl. 3):S318-S326, 1990
74. Ruhnke M et al: Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis. *J Antimicrob Chemother* **35**:641-647, 1995
75. Toon S et al: An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole. *Br J Clin Pharmacol* **29**:221-226, 1990
76. Solomon BA et al: Fluconazole for the treatment of tinea capitis in children. *J Am Acad Dermatol* **37**:274-275, 1997
77. Foster KW et al: A randomized controlled trial assessing the efficacy of fluconazole in the treatment of pediatric tinea capitis. *J Am Acad Dermatol* **53**:798-809, 2005
78. Sobel JD et al: Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. *N Engl J Med* **351**:876-883, 2004
79. Martinez RC et al: Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14. *Lett Appl Microbiol* **48**:269-274, 2009
80. Hamza OJ et al: Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: A randomized, double-blind, double-dummy trial. *Clin Infect Dis* **47**:1270-1276, 2008
81. Del Aguila R et al: Once-weekly oral doses of fluconazole 150 mg in the treatment of tinea pedis. *Clin Exp Dermatol* **17**:402-406, 1992
82. Havu V et al: A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. *Br J Dermatol* **142**:97-102, 2000
83. Faergemann J: Treatment of pityriasis versicolor with a single dose of fluconazole. *Acta Derm Venereol* **72**:74-75, 1992

84. Partap R et al: Single-dose fluconazole versus itraconazole in pityriasis versicolor. *Dermatology* **208**:55-59, 2004
85. Comert A et al: Efficacy of oral fluconazole in the treatment of seborrheic dermatitis: A placebo-controlled study. *Am J Clin Dermatol* **8**:235-238, 2007
86. Martin MV: The use of fluconazole and itraconazole in the treatment of *Candida albicans* infections: A review. *J Antimicrob Chemother* **44**:429-437, 1999
87. Diflucan. *PDR Guide to Drug Interactions, Side Effects, and Indications*. Montvale, NJ, Thomson PDR, 2006
88. Oral fluconazole for vaginal candidiasis. *Med Lett Drugs Ther* **36**:81-82, 1994
89. Pappas PG et al: Alopecia associated with fluconazole therapy. *Ann Intern Med* **123**:354-357, 1995
90. Somchit N et al: Hepatotoxicity induced by antifungal drugs itraconazole and fluconazole in rats: A comparative in vivo study. *Hum Exp Toxicol* **23**:519-525, 2004
91. Tholakanahalli VN et al: Fluconazole-induced torsade de pointes. *Ann Pharmacother* **35**:432-434, 2001
92. Pasqualotto AC et al: Voriconazole therapeutic drug monitoring: Focus on safety. *Expert Opin Drug Saf* **9**:125-137, 2010
93. Chen SC, Sorrell TC: Antifungal agents. *Med J Aust* **187**:404-409, 2007
94. Malani AN, Aronoff DM: Voriconazole-induced photosensitivity. *Clin Med Res* **6**:83-85, 2008
95. Auffret N et al: [Voriconazole photosensitivity: 7 cases]. *Ann Dermatol Venereol* **133**:330-332, 2006
96. Racette AJ et al: Photoaging and phototoxicity from long-term voriconazole treatment in a 15-year-old girl. *J Am Acad Dermatol* **52**:S81-85, 2005
97. Dolan CK et al: Pseudoporphyria as a result of voriconazole use: A case report. *Int J Dermatol* **43**:768-771, 2004
98. Tolland JP, McKeown PP, Corbett JR: Voriconazole-induced pseudoporphyria. *Photodermatol Photoimmunol Photomed* **23**:29-31, 2007
99. Huang DB, Wu JJ, Lahart CJ: Toxic epidermal necrolysis as a complication of treatment with voriconazole. *South Med J* **97**:1116-1117, 2004
100. Curigliano G et al. Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy. *Ann Oncol* **17**:1174-1175, 2006
101. Miller DD et al: Maleoma associated with Long-term voriconazole therapy: A new manifestation of chronic photosensitivity. *Arch Dermatol* **146**:300-304, 2010
102. Gupta AK, Sauder DN, Shear NH: Antifungal agents: An overview. Part I. *J Am Acad Dermatol* **30**:677-98; quiz 698-700, 1994
103. Meinhof W: Kinetics and spectrum of activity of oral antifungals: The therapeutic implications. *J Am Acad Dermatol* **29**:S37-41, 1993
104. Castellsague J et al: Risk of serious skin disorders among users of oral antifungals: A population-based study. *BMC Dermatol* **2**:14, 2002
105. Faergemann J et al: A multicentre (double-blind) comparative study to assess the safety and efficacy of fluconazole and griseofulvin in the treatment of tinea corporis and tinea cruris. *Br J Dermatol* **136**:575-577, 1997
106. Grifulvin V. *PDR Guide to Drug Interactions, Side Effects, and Indications*. Montvale, NJ, Thomson PDR, 2006
107. Gris-PEG. *PDR Guide to Drug Interactions, Side Effects, and Indications*. Montvale, NJ, Thomson PDR, 2006
108. Vassileva SG, Mateev G, Parish LC: Antimicrobial photosensitive reactions. *Arch Intern Med* **158**:1993-2000, 1998
109. Callaghan CJ, Bradley JA: Current status of renal transplantation. *Methods Mol Biol* **333**:1-28, 2006
110. Cecka JM: The OPTN/UNOS Renal Transplant Registry 2003. *Clin Transpl* **1**-12, 2003
111. Perera GK et al: Skin lesions in adult liver transplant recipients: A study of 100 consecutive patients. *Br J Dermatol* **154**:868-872, 2006
112. Richardson MD: Changing patterns and trends in systemic fungal infections. *J Antimicrob Chemother* **56**(Suppl. 1):i5-i11, 2005
113. Phillips P et al: A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. *Clin Infect Dis* **26**:1368-1373, 1998
114. Potter M: Strategies for managing systemic fungal infection and the place of itraconazole. *J Antimicrob Chemother* **56**(Suppl. 1):i49-i54, 2005
115. Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. *Clin Infect Dis* **42**:1179-1186, 2006

116. Turner MS, Drew RH, Perfect JR: Emerging echinocandins for treatment of invasive fungal infections. *Expert Opin Emerg Drugs* 11:231-250, 2006
117. Rand S: Overview: The treatment of dermatophytosis. *J Am Acad Dermatol* 43:S104-112, 2000

